PRDX5 (peroxiredoxin 5), a top M1 target selected in our RHI vs. CTL classification models, is an antioxidant enzyme expressed in neuronal mitochondria shown to be increased in postmortem brains of patients with multiple sclerosis and Huntington’s disease [52]. The gene discussed is PRDX5; the disease is juvenile Huntington disease.